Researcher Profile

Researcher Profile

Cristina Truica, MD

Cristina Truica, MD

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Breast Cancer
cit2@psu.edu

Research Interests

  • Neoplasms
  • Breast Neoplasms
  • Therapeutics
  • Circulating Neoplastic Cells
  • Drug Therapy
  • Immunotherapy
  • Equipment and Supplies
  • Safety
  • Aromatase Inhibitors
  • Survival
  • exemestane
  • Catenins

Clinical Trials

Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices
Phase II Palbociclib with Fulvestrant in Individuals with Hormone Receptive Positive HER2 Negative Metastatic Breast Cancer who progressed on treatment with Palbociclib + an Aromatase Inhibitor
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of:The CompassHER2 Trials (COMprehensive use of Pathologic response Assessment to optimize therapy in HER2-positive breast cancer).
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
General Protocol for the Acquisition of Whole Blood for the Detection and Characterization of Circulating Tumor Cells and/or Tumor Specific Immunity/Immune Cell Activation for any Malignancy at any Stage of Disease
Predicting Breast Cancer Metastasis: Signaling Pathway Biomarker Identification Using Reverse Phase Protein Microarray (RPMA) Technology

Recent Publications

2021

Nesterova, D, Zhu, J, Kramer, C, Vasekar, M, Truica, C, Joshi, A, Hayes, M, Kessler, J, Saunders, EFH, Drabick, J & Joshi, M 2021, 'Group-led creative writing and behavioural health in cancer: a randomised clinical trial', BMJ Supportive and Palliative Care. https://doi.org/10.1136/bmjspcare-2020-002463
Schmitz, KH, Schleicher, E, Doerksen, S, Truica, C, Cream, L, Kass, R, Farnan, M, Suess, R, Gordon, B, Zucker, D & Hayes, M 2021, 'Testing the acceptability and feasibility of a tablet-based supportive cancer platform for patients with metastatic breast cancer', Journal of Cancer Survivorship, vol. 15, no. 3, pp. 410-413. https://doi.org/10.1007/s11764-021-01021-x

2020

Yin, M, Verschraegen, C, Vincent, VH, Patel, SM, George, T & Truica, CI 2020, 'Impact of lack of surgery on outcomes in elderly women with nonmetastatic breast cancer-A surveillance, epidemiology, and end results 18 population based study', Medicine (United States), vol. 99, no. 3, e18745. https://doi.org/10.1097/MD.0000000000018745
Castaman, G, Borchiellini, A, Santagostino, E, Radossi, P, Aksu, S, Yilmaz, M, Serban, M, Uscatescu, V, Truica, C, Fasulo, MR, Mancuso, ME, Paladino, E, Valpreda, A, Guarnieri, C, Macchia, R, Scarpellini, M, Mathew, P & Morfini, M 2020, 'Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate', European Journal of Pharmaceutical Sciences, vol. 153, 105485. https://doi.org/10.1016/j.ejps.2020.105485
Schmitz, KH, Potiaumpai, M, Schleicher, EA, Wolf, LJ, Doerksen, SE, Drabick, JJ, Yee, NS, Truica, CI, Mohamed, AA, Shaw, BW & Farley, DC 2021, 'The exercise in all chemotherapy trial', Cancer, vol. 127, no. 9, pp. 1507-1516. https://doi.org/10.1002/cncr.33390

2019

Zhu, J, Hussain, M, Joshi, A, Truica, CI, Nesterova, D, Collins, J, Saunders, EFH, Hayes, M, Drabick, JJ & Joshi, M 2020, 'Effect of creative writing on mood in patients with cancer', BMJ Supportive and Palliative Care, vol. 10, no. 1, pp. 64-67. https://doi.org/10.1136/bmjspcare-2018-001710
Yardley, DA, Hart, L, Favret, A, Blau, S, Diab, S, Richards, D, Sparano, J, Beck, JT, Richards, P, Ward, P, Ramaswamy, B, Tsai, M, Blackwell, K, Pluard, T, Tolaney, SM, Esteva, FJ, Truica, CI, Alemany, C, Volas-Redd, G, Shtivelband, M, Purkayastha, D, Dalal, AA, Miller, M & Hortobagyi, GN 2019, 'Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study', Clinical Breast Cancer, vol. 19, no. 4, pp. 268-277.e1. https://doi.org/10.1016/j.clbc.2019.02.007
Castaman, G, Borchiellini, A, Santagostino, E, Tagariello, G, Serban, M, Uscatescu, M, Truica, C, Farrugia, A & Morfini, M 2019, 'Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients', Haemophilia, vol. 25, no. 6, pp. e364-e367. https://doi.org/10.1111/hae.13828

2018

LYM-3002 investigators 2018, 'Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study', The Lancet Oncology, vol. 19, no. 11, pp. 1449-1458. https://doi.org/10.1016/S1470-2045(18)30685-5
Luo, S, Chen, G, Truica, CI, Baird, CC, Xia, Z & Lazarus, P 2018, 'Identification and quantification of novel major metabolites of the steroidal aromatase inhibitor, exemestane', Drug Metabolism and Disposition, vol. 46, no. 12, pp. 1867-1878. https://doi.org/10.1124/dmd.118.081166
Auer, BJ, Sciamanna, C, Smyth, JM, Truica, CI, Cream, LV & Mukherjee, D 2018, 'Interest among primary care patients in group problem-solving gameplay for mental health', Preventing Chronic Disease, vol. 15, no. 6, 170488. https://doi.org/10.5888/pcd15.170488
Trifa, AP, Bănescu, C, Bojan, AS, Voina, CM, Popa, Ș, Vișan, S, Ciubean, AD, Tripon, F, Dima, D, Popov, VM, Vesa, ȘC, Andreescu, M, Török-Vistai, T, Mihăilă, RG, Berbec, N, Macarie, I, Coliţă, A, Iordache, M, Cătană, AC, Farcaș, MF, Tomuleasa, C, Vasile, K, Truică, C, Todincă, A, Pop-Muntean, L, Manolache, R, Bumbea, H, Vlădăreanu, AM, Gaman, M, Ciufu, CM & Popp, RA 2018, 'MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients', American Journal of Hematology, vol. 93, no. 1, pp. 100-106. https://doi.org/10.1002/ajh.24946
Kornblum, N, Zhao, F, Manola, J, Klein, P, Ramaswamy, B, Brufsky, A, Stella, PJ, Burnette, B, Telli, M, Makower, DF, Cheema, P, Truica, CI, Wolff, AC, Soori, GS, Haley, B, Wassenaar, TR, Goldstein, LJ, Miller, KD & Sparano, JA 2018, 'Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102', Journal of Clinical Oncology, vol. 36, no. 16, pp. 1556-1563. https://doi.org/10.1200/JCO.2017.76.9331
Luo, S, Chen, G, Truica, C, Baird, CC, Leitzel, K & Lazarus, P 2018, 'Role of the UGT2B17 deletion in exemestane pharmacogenetics', Pharmacogenomics Journal, vol. 18, no. 2, pp. 295-300. https://doi.org/10.1038/tpj.2017.18
Gineyts, E, Bonnet, N, Bertholon, C, Millet, M, Pagnon-Minot, A, Borel, O, Geraci, S, Bonnelye, E, Croset, M, Suhail, A, Truica, C, Lamparella, N, Leitzel, K, Hartmann, D, Chapurlat, R, Lipton, A, Garnero, P, Ferrari, S, Clézardin, P & Rousseau, JC 2018, 'The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis', Calcified Tissue International, vol. 103, no. 5, pp. 567-580. https://doi.org/10.1007/s00223-018-0444-y

2017

Felts, JL, Zhu, J, Han, B, Smith, SJ & Truica, CI 2017, 'An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer', Breast Journal, vol. 23, no. 6, pp. 677-686. https://doi.org/10.1111/tbj.12751
Jia, H, Truica, CI, Wang, B, Wang, Y, Ren, X, Harvey, HA, Song, J & Yang, JM 2017, 'Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects', Drug Resistance Updates, vol. 32, pp. 1-15. https://doi.org/10.1016/j.drup.2017.07.002

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)